Good morning. This is David Chang. I am the Chief Executive Officer and the Director of Allogene Therapeutics. I'm very happy to welcome you to the Allogene 2021 Annual Meeting of Stockholders. As you know, we are hosting today's meeting through a virtual online platform. In order to conduct an orderly meeting, we ask you to follow the rules of conduct, which are available on the meeting materials online. While the meeting is virtual only, stockholders of record will have the opportunity to submit questions or comments through the text box located on your screen. To ask a question online, enter your question in the box below, ask a question, and click the Submit button. We will answer questions submitted that are germane to the proposals being voted on, as and if we have time. Please submit your questions now to make sure that they are reviewed and addressed.
If you intend to vote and have not already done so, you must submit your vote online now in order for it to be counted. After we describe each item to be voted on, we will close the polls. If you have already submitted your vote by proxy and do not wish to change your vote, you do not need to vote now. Before I call the meeting to order, I would like to acknowledge that we have several members of the board and management joining us today. I would also like to introduce Yogi Ransing of Ernst & Young, LLP, the company's auditors, who is available to respond to appropriate questions. The meeting will now officially come to order, and I will now turn it over to our Secretary, David Tanen.
Thank you, David. I have at this meeting a complete list of the stockholders of record of the company's common stock as of April 12, 2021, which is the record date for this meeting. I also have an affidavit certifying that on April 22, 2021, a notice of internet availability of proxy materials was deposited in the United States mail. At this time, I'd like to introduce Veer Bhavn agri, who was appointed to act as Inspector of Election at this meeting. Veer has taken and subscribed the customary oath of office to execute his duties with strict impartiality. We will file this oath with the records of the meeting. His function is to decide upon the qualifications of voters, accept their votes, and, when balloting on all matters is completed, to tally the votes.
I have been informed by the Inspector of Election that proxies have been received for 128,742,312 of the 141,485,913 shares of common stock outstanding on the record date, which represents approximately 91% of the total number of outstanding shares. This constitutes a quorum for the meeting today, and we may now carry out the business of the meeting. I will turn it over to Veer to describe the three proposals to be considered by the stockholders at this meeting.
Thank you, David. The first item of business is the election of three Class III directors to serve until the 2024 Annual Meeting and until their successors are elected. The nominees for Class III Director are Mr. John DeYoung, Dr. Franz Huemer, and Mr. Josh Kazan. The second item of business today is to approve, on an advisory basis, the compensation of the company's named executive officers, as disclosed in the proxy statement. The third and final item of business today is a ratification of the selection by the Audit Committee of the Board of Directors of Ernst & Young, LLP, as the independent registered public accounting firm of the company for the fiscal year ending December 31, 2021. We will now review if there are any questions submitted about the proposals before we close the polls.
As a reminder, we will only review and answer questions at this time that pertain to the proposals.
To ask a question online, enter your question or comment in the box below, ask a question, and click the Submit button.
There are no questions.
Because there are no questions, it is 10:04 A.M., and I now declare the polls closed for voting. The report of the Inspector of Election covering the proposals presented at this meeting is as follows. The proposal to elect the Class III directors of the company is carried. The stockholders have approved, on an advisory basis, the executive compensation of the company's named executive officers. The selection of Ernst & Young, LLP, as the company's independent registered public accounting firm for the fiscal year ending December 31, 2021, is ratified. We expect to report the voting results on a Form 8-K to be filed with the SEC within four business days after the end of this meeting. If not earlier reported, we expect to report our final voting results in an amendment to our Form 8-K within four business days after the final results are known to us.
I will now turn it over to David to close the meeting.
As there is no other business to be conducted, the Annual Meeting is now adjourned. I would like to thank each of you once again for attending. We look forward to updating you in the future on our progress.